论文部分内容阅读
“一带一路”战略和国家《中医药健康服务发展规划(2015-2020年)》分别从国家对外和对内政策两个侧面明确表达了要与沿线国家扩大在中医药领域的合作意志.中药和西药在药性分析、医疗方法、消费模式上的区别,以及国外对植物药品准入方面存在的各种壁垒是中药国际化所面临的瓶颈,因此急需在中药国际化领域的制度创新.“一带一路”战略正为中药国际化创新提供内在动力、创新思路和全新机遇.国家和政府、行业协会以及企业公司应立足中医药传统文化的传承与弘扬的历史必然,建立中药国际化相关创新制度、政策和战略.“,”The Belt and Road Initiatives and Development Plan for Traditional Chinese Medicine-Related Health Services (2015-2020) respectively from foreign and domestic policies expressed the wills that China will expand the cooperation with surrounding countries in the field of TCM (Traditional Chinese Medicine). Because of the difference in drug analysis, therapeutic approach and consumption pattern between Chinese Medicine and Western Medicine and the barriers to botanical drugs accessing in foreign countries, there is bottleneck facing by TCM internationalization. So the institutional innovation in this field is critical. The Belt and Road Initiatives are providing the inner dynamics, innovative ideas and new opportunities for the innovation of TCM internationalization. Accordingly, the state, government, industry associations and companies should create relative innovation system, policy and strategy about TCM internationalization which are based on the heritage and promoting of TCM culture.